SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

“Hmmm” is a community meme token on the Solana network, launched on July 22, 2024, through Pumpfun. It’s a derivative of Pepe the Frog but has evolved into its own distinct meme with a unique identity. The token embraces the humor and intrigue of internet culture, playing on the idea of curiosity and speculation. “Hmmm” captures a playful approach to the world of meme tokens, designed to engage a community driven by fun and the whimsical side of crypto. Hmmm, maybe this’ll send.

hmmm

The crypto token $HMMM is gaining attention, with many users discussing its potential and availability on Phantom Wallet. Community members are using terms like "rocket," "moon," and "gem" to describe the token's momentum. Some users are also speculating about the driving forces behind the recent price action.

Clanker is an autonomous agent for deploying tokens. Currently, users may request clanker to deploy an ERC-20 token on Base by tagging it @clanker on Farcaster.

tokenbot

Clanker Crypto ($CLANKER) is trending as traders discuss its potential Coinbase listing and the impact on its price. The community is focused on its limited supply of 1 million coins, speculating on possible price movements and 

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is gaining traction as a community-driven token with viral hype, trending on Stocktwits with serious volume. The community emphasizes its strength and unity, rallying behind upcoming events like Karolina Arm's sponsored fight. Discussions highlight $SLAP's ambition to become a global brand, transcending its meme origins through real-world partnerships and a dedicated community.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending as community members discuss its potential in the expanding play-to-earn and virtual world sectors, focusing on its technology that bridges blockchain with gaming. Conversations highlight the growing community, new exchange listings, and its potential within the AI and blockchain space. Some traders are also taking profits from other tokens and moving them into Virtual Protocol.

Trump For President

TRUMP CRYPTO is trending amid discussions around Donald Trump's political activities and their potential impact on the crypto market, with community members debating the legitimacy and future prospects of Trump-related digital assets. Some traders are weighing the token's potential, while others voice concerns about its performance and broader implications. The conversation extends to Trump's stance on trade, his relationship with other political figures, and the performance of other Trump-related assets.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as traders discuss its low market cap and circulating supply, anticipating a potential breakout. Some community members point to its integration with Aleph Zero, while others speculate about possible listings on major exchanges like Binance as a catalyst for significant gains. Technical analysis chatter includes mentions of oversold RSI conditions and bull flag formations.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending due to a mix of factors, including recent developments around its Alzheimer's drug, Leqembi, and speculation about potential acquisitions. Community discussions revolve around the company's strategy, pipeline, and valuation amid shifting market dynamics, with some analysts adjusting price targets and ratings.

Columbus Circle Capital Corp. I operates as a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which refer to throughout this prospectus as initial business combination. The company was founded in June 2024 and is headquartered in New York, NY.

Columbus Circle Capital Corp I - Ordinary Shares - Class A

Columbus Circle Capital ($BRR) is trending as the community discusses Eric Jackson joining the board and anticipates a potential pump, drawing comparisons to past option surges. Chatter revolves around upcoming call options and a proposed merger with ProCap BTC, with some seeing a potentially favorable risk-reward scenario due to the SPAC's NAV floor. Recent news includes updates to the merger agreement and the appointment of a new CFO.

Codatta

Codatta ($XNY) is trending as the community discusses its potential breakout, with some suggesting it's building towards a significant move. Many traders are watching its correlation with Bitcoin ($BTC), anticipating a surge if $BTC breaks resistance. Technical analysis is being shared, highlighting bullish formations and key support levels.

KraneShares Trust - KraneShares Global Humanoid and Embodied Intelligence Index ETF

KraneShares Global Humanoid and Embodied Intelligence Index ETF

$KOID is trending as discussions emerge around robotics and AI, specifically humanoid robots. Community members are actively comparing $KOID to other robotics ETFs and discussing the potential impact of Chinese investment in the sector, with some noting the fund's growing exposure and potential for long-term growth. Mentions of Elon Musk's views on robotics and humanoid development are also contributing to the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts

Latest Ratings for LYEL
 DateFirmActionFromTo Jan 2022Morgan StanleyMaintainsOverweight Jul 2021Morgan StanleyInitiates Coverage OnOverweight Jul 2021B of A SecuritiesInitiates Coverage OnBuy...

WisdomTree, Inc. ($WT)Shares of WisdomTree, which offers a suite of exchange-traded and blockchain technology products, reported third-quarter earnings per share (EPS) of $0.18 compared to $0.10 per share a year-ago. This beat the consensus estimate of $0.18, according to Yahoo Finance.The shares climbed 4.50% to $10.85 as of 9:00 am ET, in premarket trading.WisdomTree’s assets under management at the end of the third quarter was $112.6 million, up from $109.7 million at the end of the second quarter. Operating revenue came in at $109.5 million compared to the $90.4 million reported for a year earlier. This was slightly shy of the consensus estimate of $110.07 million.<figure class="image"><a href="https://stocktwits.com/symbol/WT"><img style="aspect-ratio:637/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/wt_sentiment_34b5aa54e0.png" alt="wt-sentiment.png" width="637" height="135"></a><figcaption>WT sentiment and message volume October 25, 2024 premarket as of 9:00 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Retail sentiment was ‘extremely bullish’ (95/100) with message volume reducing from a day ago, yet at ‘high.’Lyell Immunopharma, Inc. ($LYEL)Small-cap Lyell Immunopharma, a clinical-stage CART T-cell therapy biotech, said late Thursday that it has entered into a definitive agreement to acquire privately-held&nbsp; ImmPACT Bio USA Inc for $30 million in cash and 37.5 million in stock.Through the acquisition, Lyell Immunopharma will acquire worldwide rights to ImmPACT’s pipeline. The company will prioritize the development of IMPT-314 for treating B-cell lymphoma, a type of blood cancer.ImmPACT shareholders are also eligible to receive contingent consideration of 12.5 million of Lyell Immunopharma stock as milestone-based payment as well as royalties on net sales.The deal has been vetted by the board of both companies and is expected to close in the fourth quarter.The stock gained 0.94% to $1.10 in premarket trading.DexCom, Inc. ($DXCM)Glucose monitoring device manufacturer Dexcom’s shares fell in premarket trading but retail sentiment remains ‘extremely bullish.'<figure class="image"><a href="https://stocktwits.com/symbol/DXCM"><img style="aspect-ratio:632/145;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/dxcm_sentiment_f6ce5575e8.png" alt="dxcm-sentiment.png" width="632" height="145"></a><figcaption>&nbsp;DXCM sentiment and message volume October 25, 2024 premarket as of 9:00 am ET | Source:&nbsp;Stocktwits</figcaption></figure>DexCom’s third-quarter non-GAAP EPS came in at $0.45 compared to the consensus estimate of $0.43. Revenue rose 2% year-over-year from $975 million to $994.2 million. Analysts, on average, estimated a modest $990.44 million for the quarter.&nbsp;The double beat is a welcome relief after the company missed top-line expectations in the second quarter.Dexcom announced a management transition as Teri Lawver, who serves as chief commercial officer, is set to retire by the year-end. Sayer will assume her responsibilities as the company begins a search for a replacement.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dexcom-stock-plunges-despite-q3-beat-but-retail-sentiment-improves/cJ2lHI0R7u">Dexcom Stock Plunges Despite Q3 Beat But Retail Sentiment Improves</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Dexcom and WisdomTree has cheered retailers with their earnings reports, and Lyell with an M&A transaction.

WisdomTree, Lyell Immunobiopharma, DexCom Among Stocks Retailers Are Most Bullish In Friday's Premarket

Earnings news and an M&A deal have improved retail sentiment toward these 3 stocks in Friday's premarket.

Equity

Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial

Lyell Immunopharma shares fell following the release of initial clinical data from its Phase 1 trial of LYL797, a reprogrammed CAR T-cell product. The company reported some severe cases reported in...

Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 4.9%

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) rose 4.9% during mid-day trading on Thursday . The company traded as high as $2.17 and last traded at $2.16. Approximately 21,770...

Lyell Immunopharma (NASDAQ:LYEL) Trading 5.9% Higher

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report)'s stock price traded up 5.9% during mid-day trading on Thursday . The stock traded as high as $2.17 and last traded at $2.16. 158,847 shares...

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

PRESS RELEASE CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) LONDON 19 March 2024 -- CHARM Therapeutics ( CHARM , The Company ), a 3D deep-learning research company...

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024Received Orphan Drug Designation for LYL845 for the treatment of melanomaExpect to...

Commit To Buy Lyell Immunopharma At $2.50, Earn 57.3% Annualized Using Options

Investors eyeing a purchase of Lyell Immunopharma Inc (LYEL) shares, but tentative about paying the going market price of 2.84/share, might benefit from considering selling puts among the...

Lyell Immunopharma Announces Participation in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Lyell Immunopharma Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

LYEL
Lyell Immunopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LYEL News

LYELLyell Immunopharma Inc